1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: B-Cell Maturation Antigen (BCMA) Targeted Therapies Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, by Therapy Type
8.1.1. CAR-T Cell Therapies (Autologous & Allogeneic)
8.1.1.1. Market Revenue and Forecast
8.1.2. Bispecific Antibodies (T-cell Engagers)
8.1.2.1. Market Revenue and Forecast
8.1.3. Antibody-Drug Conjugates (ADCs)
8.1.3.1. Market Revenue and Forecast
9.1. B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, by Indication
9.1.1. Multiple Myeloma (Relapsed/Refractory)
9.1.1.1. Market Revenue and Forecast
9.1.2. Earlier-line Multiple Myeloma
9.1.2.1. Market Revenue and Forecast
9.1.3. Other Hematologic Malignancies (Emerging Indications)
9.1.3.1. Market Revenue and Forecast
10.1. B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, by Targeting Mechanism
10.1.1. BCMA-directed T-cell Activation
10.1.1.1. Market Revenue and Forecast
10.1.2. BCMA-targeted Cytotoxic Delivery (ADC-based)
10.1.2.1. Market Revenue and Forecast
10.1.3. Dual-targeting/Multi-antigen Approaches
10.1.3.1. Market Revenue and Forecast
11.1. B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, by Route of Administration
11.1.1. Intravenous (IV)
11.1.1.1. Market Revenue and Forecast
11.1.2. Subcutaneous (SC)
11.1.2.1. Market Revenue and Forecast
12.1. B-Cell Maturation Antigen (BCMA) Targeted Therapies Market, by End-Use
12.1.1. Hospitals & Cancer Centers
12.1.1.1. Market Revenue and Forecast
12.1.2. Specialty Oncology Clinics
12.1.2.1. Market Revenue and Forecast
12.1.3. Academic & Research Institutes
12.1.3.1. Market Revenue and Forecast
13.1. North America
13.1.1. Market Revenue and Forecast, by Therapy Type
13.1.2. Market Revenue and Forecast, by Indication
13.1.3. Market Revenue and Forecast, by Targeting Mechanism
13.1.4. Market Revenue and Forecast, by Route of Administration
13.1.5. Market Revenue and Forecast, by End-Use
13.1.6. U.S.
13.1.6.1. Market Revenue and Forecast, by Therapy Type
13.1.6.2. Market Revenue and Forecast, by Indication
13.1.6.3. Market Revenue and Forecast, by Targeting Mechanism
13.1.6.4. Market Revenue and Forecast, by Route of Administration
13.1.6.5. Market Revenue and Forecast, by End-Use
13.1.7. Rest of North America
13.1.7.1. Market Revenue and Forecast, by Therapy Type
13.1.7.2. Market Revenue and Forecast, by Indication
13.1.7.3. Market Revenue and Forecast, by Targeting Mechanism
13.1.7.4. Market Revenue and Forecast, by Route of Administration
13.1.7.5. Market Revenue and Forecast, by End-Use
13.2. Europe
13.2.1. Market Revenue and Forecast, by Therapy Type
13.2.2. Market Revenue and Forecast, by Indication
13.2.3. Market Revenue and Forecast, by Targeting Mechanism
13.2.4. Market Revenue and Forecast, by Route of Administration
13.2.5. Market Revenue and Forecast, by End-Use
13.2.6. UK
13.2.6.1. Market Revenue and Forecast, by Therapy Type
13.2.6.2. Market Revenue and Forecast, by Indication
13.2.6.3. Market Revenue and Forecast, by Targeting Mechanism
13.2.7. Market Revenue and Forecast, by Route of Administration
13.2.8. Market Revenue and Forecast, by End-Use
13.2.9. Germany
13.2.9.1. Market Revenue and Forecast, by Therapy Type
13.2.9.2. Market Revenue and Forecast, by Indication
13.2.9.3. Market Revenue and Forecast, by Targeting Mechanism
13.2.10. Market Revenue and Forecast, by Route of Administration
13.2.11. Market Revenue and Forecast, by End-Use
13.2.12. France
13.2.12.1. Market Revenue and Forecast, by Therapy Type
13.2.12.2. Market Revenue and Forecast, by Indication
13.2.12.3. Market Revenue and Forecast, by Targeting Mechanism
13.2.12.4. Market Revenue and Forecast, by Route of Administration
13.2.13. Market Revenue and Forecast, by End-Use
13.2.14. Rest of Europe
13.2.14.1. Market Revenue and Forecast, by Therapy Type
13.2.14.2. Market Revenue and Forecast, by Indication
13.2.14.3. Market Revenue and Forecast, by Targeting Mechanism
13.2.14.4. Market Revenue and Forecast, by Route of Administration
13.2.15. Market Revenue and Forecast, by End-Use
13.3. APAC
13.3.1. Market Revenue and Forecast, by Therapy Type
13.3.2. Market Revenue and Forecast, by Indication
13.3.3. Market Revenue and Forecast, by Targeting Mechanism
13.3.4. Market Revenue and Forecast, by Route of Administration
13.3.5. Market Revenue and Forecast, by End-Use
13.3.6. India
13.3.6.1. Market Revenue and Forecast, by Therapy Type
13.3.6.2. Market Revenue and Forecast, by Indication
13.3.6.3. Market Revenue and Forecast, by Targeting Mechanism
13.3.6.4. Market Revenue and Forecast, by Route of Administration
13.3.7. Market Revenue and Forecast, by End-Use
13.3.8. China
13.3.8.1. Market Revenue and Forecast, by Therapy Type
13.3.8.2. Market Revenue and Forecast, by Indication
13.3.8.3. Market Revenue and Forecast, by Targeting Mechanism
13.3.8.4. Market Revenue and Forecast, by Route of Administration
13.3.9. Market Revenue and Forecast, by End-Use
13.3.10. Japan
13.3.10.1. Market Revenue and Forecast, by Therapy Type
13.3.10.2. Market Revenue and Forecast, by Indication
13.3.10.3. Market Revenue and Forecast, by Targeting Mechanism
13.3.10.4. Market Revenue and Forecast, by Route of Administration
13.3.10.5. Market Revenue and Forecast, by End-Use
13.3.11. Rest of APAC
13.3.11.1. Market Revenue and Forecast, by Therapy Type
13.3.11.2. Market Revenue and Forecast, by Indication
13.3.11.3. Market Revenue and Forecast, by Targeting Mechanism
13.3.11.4. Market Revenue and Forecast, by Route of Administration
13.3.11.5. Market Revenue and Forecast, by End-Use
13.4. MEA
13.4.1. Market Revenue and Forecast, by Therapy Type
13.4.2. Market Revenue and Forecast, by Indication
13.4.3. Market Revenue and Forecast, by Targeting Mechanism
13.4.4. Market Revenue and Forecast, by Route of Administration
13.4.5. Market Revenue and Forecast, by End-Use
13.4.6. GCC
13.4.6.1. Market Revenue and Forecast, by Therapy Type
13.4.6.2. Market Revenue and Forecast, by Indication
13.4.6.3. Market Revenue and Forecast, by Targeting Mechanism
13.4.6.4. Market Revenue and Forecast, by Route of Administration
13.4.7. Market Revenue and Forecast, by End-Use
13.4.8. North Africa
13.4.8.1. Market Revenue and Forecast, by Therapy Type
13.4.8.2. Market Revenue and Forecast, by Indication
13.4.8.3. Market Revenue and Forecast, by Targeting Mechanism
13.4.8.4. Market Revenue and Forecast, by Route of Administration
13.4.9. Market Revenue and Forecast, by End-Use
13.4.10. South Africa
13.4.10.1. Market Revenue and Forecast, by Therapy Type
13.4.10.2. Market Revenue and Forecast, by Indication
13.4.10.3. Market Revenue and Forecast, by Targeting Mechanism
13.4.10.4. Market Revenue and Forecast, by Route of Administration
13.4.10.5. Market Revenue and Forecast, by End-Use
13.4.11. Rest of MEA
13.4.11.1. Market Revenue and Forecast, by Therapy Type
13.4.11.2. Market Revenue and Forecast, by Indication
13.4.11.3. Market Revenue and Forecast, by Targeting Mechanism
13.4.11.4. Market Revenue and Forecast, by Route of Administration
13.4.11.5. Market Revenue and Forecast, by End-Use
13.5. Latin America
13.5.1. Market Revenue and Forecast, by Therapy Type
13.5.2. Market Revenue and Forecast, by Indication
13.5.3. Market Revenue and Forecast, by Targeting Mechanism
13.5.4. Market Revenue and Forecast, by Route of Administration
13.5.5. Market Revenue and Forecast, by End-Use
13.5.6. Brazil
13.5.6.1. Market Revenue and Forecast, by Therapy Type
13.5.6.2. Market Revenue and Forecast, by Indication
13.5.6.3. Market Revenue and Forecast, by Targeting Mechanism
13.5.6.4. Market Revenue and Forecast, by Route of Administration
13.5.7. Market Revenue and Forecast, by End-Use
13.5.8. Rest of LATAM
13.5.8.1. Market Revenue and Forecast, by Therapy Type
13.5.8.2. Market Revenue and Forecast, by Indication
13.5.8.3. Market Revenue and Forecast, by Targeting Mechanism
13.5.8.4. Market Revenue and Forecast, by Route of Administration
13.5.8.5. Market Revenue and Forecast, by End-Use
14.1. Bristol Myers Squibb
14.1.1. Company Overview
14.1.2. Product Offerings
14.1.3. Financial Performance
14.1.4. Recent Initiatives
14.2. Johnson & Johnson
14.2.1. Company Overview
14.2.2. Product Offerings
14.2.3. Financial Performance
14.2.4. Recent Initiatives
14.3. GSK plc
14.3.1. Company Overview
14.3.2. Product Offerings
14.3.3. Financial Performance
14.3.4. Recent Initiatives
14.4. Amgen Inc.
14.4.1. Company Overview
14.4.2. Product Offerings
14.4.3. Financial Performance
14.4.4. Recent Initiatives
14.5. Regeneron Pharmaceuticals, Inc.
14.5.1. Company Overview
14.5.2. Product Offerings
14.5.3. Financial Performance
14.5.4. Recent Initiatives
14.6. Sanofi S.A
14.6.1. Company Overview
14.6.2. Product Offerings
14.6.3. Financial Performance
14.6.4. Recent Initiatives
14.7. Novartis AG
14.7.1. Company Overview
14.7.2. Product Offerings
14.7.3. Financial Performance
14.7.4. Recent Initiatives
14.8. Pfizer Inc.
14.8.1. Company Overview
14.8.2. Product Offerings
14.8.3. Financial Performance
14.8.4. Recent Initiatives
14.9. Legend Biotech Corporation
14.9.1. Company Overview
14.9.2. Product Offerings
14.9.3. Financial Performance
14.9.4. Recent Initiatives
14.10. Bluebird Bio, Inc.
14.10.1. Company Overview
14.10.2. Product Offerings
14.10.3. Financial Performance
14.10.4. Recent Initiatives
15.1. Primary Research
15.2. Secondary Research
15.3. Assumptions
16.1. About Us
16.2. Glossary of Terms
For questions or customization requests, please reach out to us at sales@precedenceresearch.com
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
